Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae

BMC Research Notes

Volumn 3, Issue , 2010, Pages

  Chaubey, Vikas P ^a   Pitout, Johann D D ^b,c   Dalton, Bruce ^a,d   Ross, Terry ^b   Church, Deirdre L ^a   Gregson, Daniel B ^a,b,c   Laupland, Kevin B ^a,b,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

^d ALBERTA HEALTH SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 77952914791     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-3-116     Document Type: Article

References (29)

1. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. JD Pitout KB Laupland, Lancet Infect Dis 2008 8 159 166 10.1016/S1473-3099(08)70041-0 18291338
2. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. A Apisarnthanarak P Kiratisin LM Mundy, Infect Control Hosp Epidemiol 2008 29 671 674 10.1086/588082 18624669 (Pubitemid 352009396)
3. Clinical features and outcome of community-onset bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. CI Kang HS Cheong DR Chung KR Peck JH Song MD Oh, et al. Eur J Clin Microbiol Infect Dis 2008 27 85 88 10.1007/s10096-007-0401-6 17943331
4. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. TM Coque F Baquero R Canton, Euro Surveill 2008 13
5. In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. RN Jones SG Jenkins DJ Hoban MA Pfaller R Ramphal, Int J Antimicrob Agents 2000 15 111 118 10.1016/S0924- 8579(00)00152-7 10854806 (Pubitemid 30347251)
6. Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. PL Winokur R Canton JM Casellas N Legakis, Clin Infect Dis 2001 32 Suppl 2 94 103 10.1086/320182 11320450
7. High levels of antimicrobial coresistance among extended-spectrum-beta- lactamase-producing Enterobacteriaceae. MJ Schwaber S Navon-Venezia D Schwartz Y Carmeli, Antimicrob Agents Chemother 2005 49 2137 2139 10.1128/AAC.49.5.2137- 2139.2005 15855548
8. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. BN Kim JH Woo MN Kim J Ryu YS Kim, J Hosp Infect 2002 52 99 106 10.1053/jhin.2002.1288 12392901
9. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. E Lautenbach JB Patel WB Bilker PH Edelstein NO Fishman, Clin Infect Dis 2001 32 1162 1171 10.1086/319757 11283805
10. Clinical and economic impact of bacteremia with extended-spectrum-beta- lactamase-producing Enterobacteriaceae. MJ Schwaber S Navon-Venezia KS Kaye R Ben-Ami D Schwartz Y Carmeli, Antimicrob Agents Chemother 2006 50 1257 1262 10.1128/AAC.50.4.1257-1262.2006 16569837
11. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. MJ Schwaber Y Carmeli, J Antimicrob Chemother 2007 60 913 920 10.1093/jac/dkm318 17848376
12. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. KB Laupland DB Gregson DL Church T Ross JD Pitout, Clin Microbiol Infect 2008 14 1041 1047 10.1111/j.1469-0691.2008. 02089.x 19040476
13. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. H Quan V Sundararajan P Halfon A Fong B Burnand JC Luthi, et al. Med Care 2005 43 1130 1139 10.1097/01.mlr.0000182534.19832.83 16224307
14. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. H Quan B Li LD Saunders GA Parsons CI Nilsson A Alibhai, et al. Health Serv Res 2008 43 1424 1441 10.1111/j.1475-6773.2007.00822.x 18756617
15. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. V Sundararajan T Henderson C Perry A Muggivan H Quan WA Ghali, J Clin Epidemiol 2004 57 1288 1294 10.1016/j.jclinepi.2004.03.012 15617955
16. An electronic application for rapidly calculating Charlson comorbidity score. WH Hall R Ramachandran S Narayan AB Jani S Vijayakumar, BMC Cancer 2004 4 94 10.1186/1471-2407-4-94 15610554
17. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. MD Parkins DM Sabuda S Elsayed KB Laupland, J Antimicrob Chemother 2007 60 613 618 10.1093/jac/dkm212 17576697
18. Performance Standards for Antimicrobial Susceptibility Testing. Clinical and Laboratory Standards Institute, 18th informational supplement M100-S18. 2009 Wayne, CLSI 2008
19. Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. JD Pitout DL Church DB Gregson BL Chow M McCracken MR Mulvey, et al. Antimicrob Agents Chemother 2007 51 1281 1286 10.1128/AAC.01377-06 17283198
20. Development and clinical validation of a molecular diagnostic assay to detect CTX-M-type beta-lactamases in Enterobacteriaceae. JD Pitout N Hamilton DL Church P Nordmann L Poirel, Clin Microbiol Infect 2007 13 291 297 10.1111/j.1469-0691.2006.01645.x 17391384
21. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. JD Pitout DB Gregson L Campbell KB Laupland, Antimicrob Agents Chemother 2009 53 2846 2851 10.1128/AAC.00247-09 19380595
22. Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. JD Pitout ND Hanson DL Church KB Laupland, Clin Infect Dis 2004 38 1736 1741 10.1086/421094 15227620
23. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. A Kumar D Roberts KE Wood B Light JE Parrillo S Sharma, et al. Crit Care Med 2006 34 1589 1596 10.1097/01.CCM.0000217961.75225.E9 16625125
24. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. S Harbarth J Garbino J Pugin JA Romand D Lew D Pittet, Am J Med 2003 115 529 535 10.1016/j.amjmed.2003.07.005 14599631
25. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. DS Burgess RG Hall JS Lewis JH Jorgensen JE Patterson, Pharmacotherapy 2003 23 1232 1237 10.1592/phco.23.12.1232.32706 14594340
26. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. DL Paterson WC Ko GA von S Mohapatra JM Casellas H Goossens, et al. Clin Infect Dis 2004 39 31 37 10.1086/420816 15206050
27. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. E Lautenbach BL Strom WB Bilker JB Patel PH Edelstein NO Fishman, Clin Infect Dis 2001 33 1288 1294 10.1086/322667 11565067
28. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. E Lautenbach JP Metlay WB Bilker PH Edelstein NO Fishman, Clin Infect Dis 2005 41 923 929 10.1086/432940 16142655
29. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. A Endimiani F Luzzaro M Perilli G Lombardi A Coli A Tamborini, et al. Clin Infect Dis 2004 38 243 251 10.1086/380645 14699457